. 2020 Aug 10;17:42. doi: 10.1186/s12970-020-00371-8

Table 3.

Comparison of baseline (mean ± SD) and mean (±95% CI) changes for blood related markers

Measure	Pre	Change DRIB	Change PLAC	Group p-value
Creatine kinase(U·L^− 1)	71.52(12.09)
P 24		98.88(− 127.87, −71.90)^a	153.74(− 181.98, − 123.28)^a	0.002^c
P 48		81.21(− 135.65, − 28.77)^a	138.17(− 193.11, − 81.02)^a	0.079
Lactate Dehydrogenase(U·L^− 1)	142.18(50.74)
P 24		49.17(−98.68, 5.17)	114.97 (− 172.08, − 63.16)^a	0.005^c
P 48		34.01(−73.42, 10.21)	162.59(− 209.09, − 121.38)^a	< 0.001^c
Myoglobin (ng·ml^− 1)	46.55(26.85)
P 24		50.66(− 113.81, − 55.37)^a	86.44(− 54.14, − 15.61)^a	0.006^c
P 48		16.45(− 124.11, −62.82)^a	29.85(−60.99, − 20.58)^a	0.230
Superoxide dismutase(U·ml^− 1)	48.37(7.57)
P 24		11.91(−17.92, − 4.8)^a	11.6(− 40.12, − 15.25)^a	0.932
P 48		28.23(− 19.09, − 5.32)^a	16.66(−30.3, − 4.22)^a	0.077
Total antioxidant capacity(U·ml^− 1)	3.59(2.19)
P 24		21.48(−30.16, − 12.06)^a	14.97(−23.49, − 10.48)^a	0.157
P 48		17.36(−24.87, − 5.89)^a	13.11(− 20.34, − 6.7)^a	0.248
Malondialdehyde(U·ml^− 1)	4.02(1.39)
P 24		1.37(− 3.98, 0.2)	3.75(−1.33, 0.78)^a	0.029^b
P 48		−0.25(− 5.36, − 0.98)	2.87(− 3.41, − 1.19)^a	< 0.001^c

DRIB D-ribose group, PLAC Placebo group

^a99% CI changes that failed to cross 0 indicates a significant difference vs. Pre

^bindicates a significant difference vs. Placebo group (p < 0.05)

^cindicates a significant difference vs. Placebo group (p < 0.01)